Potent antimitotic and cell growth inhibitory properties of substituted chalcones

Bioorganic and Medicinal Chemistry Letters

Volumn 8, Issue 9, 1998, Pages 1051-1056

  Ducki, Sylvie ^a,b   Forrest, Richard ^a   Hadfield, John A ^b   Kendall, Alex ^a   Lawrence, Nicholas J ^a   McGown, Alan T ^b   Rennison, David ^a,b  

^a UNIVERSITY OF MANCHESTER   (United Kingdom)

^b CHRISTIE HOSPITAL   (United Kingdom)

Author keywords

Antitumour compounds; Chalcones; Molecular modelling mechanics; X ray crystal structures

Indexed keywords

ANTIMITOTIC AGENT; CHALCONE;

ANTINEOPLASTIC ACTIVITY; ARTICLE; CELL GROWTH; CRYSTAL STRUCTURE; CYTOTOXICITY; DRUG ISOLATION; DRUG POTENCY; DRUG SYNTHESIS; GROWTH INHIBITION; LEUKEMIA CELL LINE; MITOSIS INDEX; MOLECULAR MODEL; NONHUMAN; X RAY CRYSTALLOGRAPHY;

ANTINEOPLASTIC AGENTS; CELL CYCLE; CELL DIVISION; CELL SURVIVAL; CHALCONE; CRYSTALLOGRAPHY, X-RAY; DRUG DESIGN; HUMANS; K562 CELLS; MODELS, MOLECULAR; MOLECULAR CONFORMATION; MOLECULAR STRUCTURE; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 0032080796     PISSN: 0960894X     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0960-894X(98)00162-0     Document Type: Article

References (30)

1. 1 'Human medicinal agents from plants', eds. Kinghorn, A. D.; Balandrin, M. F.; ACS symposium series, 534, American Chemical Society, Washington, DC, 1993.
2. 2 Qian, B. Clinical Effects of Anticancer Chinese Medicine, Shanghai Translation Publishing House, 1987.
3. 3 Ducki, S.; Hadfield, J. A.; Lawrence, N. J.; Liu, C.-Y.; McGown, A. T.; Zhang, X. G. Planta Medica, 1996, 62, 185.
4. 4 Ducki, S.; Hadfield, J. A; Hepworth, L. A.; Lawrence, N. J.; Liu, C.-Y.; McGown, A. T. Biorg. Med. Chem. Lett., 1997, 7, 3091.
5. 5 Edmondson, J. M.; Armstrong, L. S.; Martinez, A. O. J. Tissue Culture Methods, 1988,11, 15.
6. 6 Ducki, S.; Hadfield, J. A.; Lawrence, N. J.; McGown, A. T. manuscript in preparation.
7. 7 Ikeda, S.; Kimura, U.; Ashizawa, T.; Gomi, K.; Saito, H. 'Preparation of chalcone derivatives as antitumor agents', 1996, Jpn. Kokai Tokkyo Koho JP 08,188,546; Chem. Abs., 1996, 725, 221359a.
8. 7 Ikeda, S.; Kimura, U.; Ashizawa, T.; Gomi, K.; Saito, H. 'Preparation of chalcone derivatives as antitumor agents', 1996, Jpn. Kokai Tokkyo Koho JP 08,188,546; Chem. Abs., 1996, 725, 221359a.
9. 3). The combined organic layers were dried over anhydrous magnesium sulfate, filtered and evaporated in vacua. The residue was purified by column chromatography.
10. 3). The combined organic layers were dried over anhydrous magnesium sulfate, filtered and evaporated in vacua. The residue was purified by column chromatography.
11. 3). The combined organic layers were dried over anhydrous magnesium sulfate, filtered and evaporated in vacua. The residue was purified by column chromatography.
12. 9 Edwards, M. L.; Stetnerick; D. M.; Sunkara, P. S. J. Med. Chem., 1990, 33, 1948; the increase in activity of methyl substituted chalcones was not observed for all compounds in the 6 h bioassay.
13. 3) were heated under reflux and water was removed from the reaction mixture by Soxhlet extraction over 4 Å molecular sieves for 2 days. The solvent was removed in vacua and the residue was purified by column chromatography.
14. 11 Sunkara, P. S.; Zwolshen, J. H.; Stemerick, D. M.; Edwards, M. L. Am. Assoc. Cancer Res., 1991, 32, 329.
15. 12 Peyrot, V.; Leynadaer, D.; Sarrazin, M.; Briand, C; Menendez, M.; Laynez, J.; Andreu, J. M. Biochemistry, 1992, 37, 11125.
16. 13 Pettit, G. R.; Singh, S. B.; Hamel, E; Lin, C. M.; Alberts, D. S.; Garia-Kendall, D. Experientia., 1989, 45, 205.
17. 14 Full crystallographic details will be published elsewhere.
18. 15 Meyer, A. Y. in The Chemistry of Enones, part 1, eds. Patai, S and Rappaport, Z., Wiley, Chichester, 1989, 1.
19. 16 Rabinovich, D. J. Chem. Soc. (B), 1970, 11.
20. 17 Rabinovich, D.; Schmidt, G. M. J.; Snaked, Z. J. Chem. Soc., Perkin Trans. 2, 1973, 33.
21. 18 Rabinovich, D.; Shakked Z. Acta Cryst., 1974, B30, 2829.
22. 19 Zhengdong, L.; Genbo, S. Acta Cryst., 1994, C50, 126.
23. 20 Rabinovich, D.; Schmidt, G. M. J. J. Chem. Soc. (B), 1970, 6.
24. 21 Wallet, J.-C.; Molins, E.; Miravitlles, C. Acta Cryst., 1995, C51, 123.
25. 22 Bolte, M.; Schütz, G.; Bader, H. J. Acta Cryst., 1996, C52, 2807.
26. 23 DeClercq, J. P.; Germain, G.; Meerssche, M. van; L'Abbe, G. Bull. Soc. Chim. Belg., 1978, 87, 239.
27. 24 Alvarez-Builla, J.; Novella, J. L.; Galvez, E.; Smith, P.; Florencio, F.; Garcia-Blanco, S.; Bellanata, J.; Santos, M. Tetrahedron, 1986, 42, 699.
28. 25 The minimum energy conformation of combretastatin A-4 is similar to the X-ray crystal structure of the related stilbene combretastatin A-1. See Pettit, G. R.; Singh, S. G.; Niven, M. L.; Hamel, E.; Schmidt, J. M. J. Nat. Prod., 1987, 50, 119.
29. 26 Lessinger, L.; Margulis, T. N. Acta Cryst. Sec. B, 1978, 34, 578.
30. 27 McGown, A. T.; Fox, B. W. Anti-Cancer Drug Design, 1989, 3, 249.